Related by context. All words. (Click for frequent words.) 72 pharmacokinetics PK 71 pharmacokinetics pharmacodynamics 71 preclinical efficacy 68 pharmacokinetic characteristics 68 pharmacodynamic PD 67 CRLX# 67 Phase 1a clinical 67 pharmacokinetic PK 67 pharmacokinetic PK profile 67 pharmacokinetic 66 pharmacokinetic parameters 66 dose proportionality 66 pharmacodynamic properties 66 preclinical pharmacokinetic 66 thorough QT 66 pharmacokinetic PK study 66 pharmacodynamics 65 Phase Ib study 65 ORMD 65 GAMMAGARD 65 PK PD 65 Pharmacokinetic 65 neratinib 65 pharmacodynamic parameters 65 safety tolerability pharmacokinetic 65 viral kinetic 65 relapsed MM 65 phase Ib 65 pharmacodynamic markers 64 multicenter Phase II 64 vivo preclinical 64 indibulin 64 pharmacodynamic 64 viral kinetics 64 Oral NKTR 64 double blinded randomized 64 farletuzumab 64 favorable pharmacokinetic profile 64 pharmacokinetic studies 64 Kahalalide F 64 pharmacodynamic effects 64 trodusquemine 63 teriflunomide 63 Capesaris 63 DermaVir Patch 63 CardioPET 63 pharmacodynamics PD 63 riociguat 63 ascending dose 63 demonstrated antitumor activity 63 secondary efficacy endpoints 63 HuMax EGFr 63 preclinically 63 tolerability pharmacokinetics 63 analgesic efficacy 63 clevidipine 63 Zemplar Capsules 63 Phase Ib clinical 63 galiximab 63 Meta analyzes 63 solithromycin 63 SIMPADICO 63 oral talactoferrin 63 radezolid 63 placebo controlled dose escalation 63 Virulizin ® 63 preclinical pharmacology 63 phase IIIb 63 pharmacokinetic pharmacodynamic PK PD 63 pharmacokinetic profiles 63 Phase 1b trial 62 prospective multicentre 62 biostatistical analysis 62 velafermin 62 CA9 SCAN 62 PHX# 62 trastuzumab emtansine T DM1 62 alvespimycin 62 Randomized controlled 62 Phase Ia 62 subcutaneous PRO 62 CG# [003] 62 Trofex 62 blinded randomized 62 vidofludimus 62 ongoing Phase 1b 62 TRO# 62 Pharmacodynamic 62 LCP Tacro 62 MEND CABG II 62 maximally tolerated dose 62 NP2 Enkephalin 62 EOquin TM 62 vivo pharmacology 62 Phase IIb III 62 antiangiogenic therapy 62 rALLy trial 62 OvaRex MAb 62 Thorough QT 62 Cloretazine 62 pain palliation 62 pharmacodynamic profile 62 pharmacodynamic PK PD 62 vitro ADME 62 NOX E# 62 PEG SN# 62 AVADO 62 busulfan 62 Pharmacokinetic studies 62 blinded randomized placebo controlled 62 lanthanum carbonate 62 DCCR 61 TQT 61 phase IIa clinical 61 dose escalation phase 61 phase IIb 61 randomized discontinuation 61 tolerability profiles 61 Vectibix monotherapy 61 STRIDE PD 61 Phase Ib II 61 clinical pharmacology studies 61 vitro cytotoxicity 61 PROSTVAC TM 61 Quinamed 61 ENMD # 61 NEUVENGE 61 fosbretabulin 61 randomized blinded 61 Pharmacokinetic parameters 61 RE SURGE 61 vinca alkaloid 61 LAB CGRP 61 oral rivaroxaban 61 INCB# [001] 61 intermittent dosing 61 EGS# 61 prospective observational studies 61 budesonide MMX 61 crizotinib PF # 61 CALGB 61 CTAP# Capsules 61 BCIRG 61 ganetespib 61 epoetin alpha 61 pomalidomide 61 MGN# 61 dose escalation trial 61 pharmacodynamic endpoints 61 single ascending dose 61 pramlintide metreleptin combination 61 randomized Phase 2b 61 CIMZIA ™ 61 serologic 61 desvenlafaxine succinate 61 EURIDIS 61 Ophena 61 NO# [002] 61 Aplidin 61 CARE HF 61 Initiated Phase 61 YONDELIS R 61 radiation dosimetry 61 hematological parameters 61 isatoribine 61 CINQUIL 61 ChronVac C R 61 Neuradiab TM 61 GCP compliant 61 varespladib 61 GRNVAC1 61 genotoxicity 61 demonstrated clinically meaningful 61 ConclusionThis 61 GetGoal Phase III 61 Biomerk Tumorgrafts 61 CANCIDAS 61 registrational Phase 61 Zalypsis 60 inecalcitol 60 TAXUS VI 60 PRESEPT 60 Traficet EN 60 nonfasting 60 phase IIa 60 ospemifene 60 multicentre randomized 60 QOPI 60 CHAMPION PCI 60 orally dosed 60 safety tolerability pharmacokinetics 60 FOSRENOL ® 60 dose escalation Phase 60 YONDELIS 60 immune modulating 60 PK PD modeling 60 ISIS # 60 elacytarabine 60 nonclinical studies 60 NSABP B 60 HGS# 60 Blinatumomab 60 MAGE A3 ASCI 60 dosing cohort 60 LibiGel Phase III 60 melphalan prednisone 60 endothelin antagonists 60 BRIM3 60 Phase #b/#a 60 Phase IIA 60 genotypic resistance 60 pharmacokinetics 60 CLORETAZINE TM VNP#M 60 acyclovir Lauriad R 60 NCIC CTG 60 Xanafide 60 antiviral efficacy 60 Pharmacokinetic PK 60 GFT# 60 NSABP 60 subcutaneous SC 60 Afatinib 60 HuMax CD#b 60 phase 2a 60 pivotal bioequivalence 60 Primary endpoints 60 Phase #/#a 60 Vascugel TM 60 sipuleucel T 60 LCP AtorFen 60 metabolomic profiling 60 CR# vcMMAE 60 Solorel TM 60 tolerability 60 HQK 60 Imprime PGG 60 Sym# 60 EXPLORE Xa 60 biostatistical 60 delafloxacin 60 ZYBRESTAT fosbretabulin 60 Pertuzumab 60 Insulin detemir 60 azilsartan medoxomil 60 basal bolus regimen 60 MoxDuo ® IR 60 multicenter Phase III 60 Secondary efficacy endpoints 60 radiolabeled TM# 60 CLIRS 60 XR NTX 60 IMA# 60 SUTENT ® 60 PrevOnco ™ 60 PSMA ADC 60 Azedra 60 DAVANAT 60 Teriflunomide 60 confirmatory clinical 60 ELACYT 60 rEEG 60 BrachySil TM 60 trastuzumab DM1 T DM1 60 sunitinib malate 60 ToGA 60 PEARL SC 60 erythropoietic 59 QTinno 59 RE LY ® 59 randomized multicenter trial 59 intradermal injections 59 IntroductionThe 59 mg/m2 dose 59 noninferiority 59 Panzem R NCD 59 MEND CABG 59 APTIVUS 59 meta regression 59 CEQ# 59 paclitaxel poliglumex 59 sapacitabine CYC# 59 ALB # 59 GLPG# 59 RE LY trial 59 ASSERT trial 59 Vaxfectin TM 59 Genz # 59 ascending doses 59 EmbraceAC 59 prospectively defined 59 budesonide MMX Phase III 59 clinico pathological 59 #T# L1 59 selenium supplementation 59 blinded randomized controlled 59 preclinical toxicology 59 urinary N telopeptide 59 BFPET 59 Neuradiab 59 CLARITY study 59 randomized crossover 59 REVIVE Diabetes 59 pertuzumab 59 OLYMPIA registry 59 MERLIN TIMI 59 rHuPH# 59 elotuzumab 59 Multimeric 59 bovine thrombin 59 Multiple logistic regression 59 SABCS 59 evaluating tivozanib 59 CYT# potent vascular disrupting 59 Phase 1b clinical 59 radiolabeled 59 PENNVAX B 59 multiple ascending dose 59 efficacy endpoint 59 Phase 1a 59 ancrod 59 PROCHYMAL 59 randomized Phase III 59 Anticalins ® 59 placebo controlled clinical 59 evaluating Actimmune 59 IMPACT DCM 59 lorcaserin Phase 59 nonrandomized 59 Alzhemed TM 59 oral antiviral 59 insulin detemir 59 samalizumab 59 TAKSTA 59 Gag polymorphisms 59 tanespimycin 59 davunetide intranasal AL 59 R#/MEM # 59 MIRCERA 59 NOD mouse 59 ataluren 59 XOMA 3AB 59 R roscovitine 59 IIa clinical 59 Phase Ib 59 radiographic outcomes 59 ON #.Na 59 BARI 2D 59 HF ACTION 59 intravenous dosing 59 oral prodrug 59 DASISION 59 mesalamine granules 59 tubulin inhibitor 59 RSD# oral 59 Multivariate logistic regression 59 Dual Opioid 59 randomized controlled Phase 59 thalidomide Thalomid 59 orally inhaled migraine 59 Onconase 59 mechanistic studies 59 observational cohort study 59 BRIM2 59 active comparator 59 cannabinor 59 CeaProve 59 optimal dosing 59 plasma pharmacokinetics 59 pharmacokinetic equivalence 59 PARTNER Trial 59 ONCONASE R 59 Novolimus 59 PD LID 59 IDO inhibitor 59 TRV# [001] 59 enzastaurin 59 retrospective cohort 59 Chemophase 59 Phase 2a clinical 59 tolevamer 59 lorvotuzumab mertansine 59 double blinded placebo 59 CCX# 59 GLP toxicology studies 59 phase IIb study 59 ORACLE MS 59 PSN# [002] 59 pafuramidine 59 Phase #/#a clinical 58 PEGPH# 58 TBC# 58 dose escalation clinical 58 MGd 58 quantitative gene expression 58 obatoclax 58 Phase 1b 58 nab paclitaxel 58 forodesine 58 Phase IIa 58 xenograft models 58 #beta estradiol 58 MVA MUC1 IL2 58 Carfilzomib 58 Azedra TM 58 NCCTG 58 Cloretazine R VNP#M 58 NEUGENE antisense 58 fidaxomicin Phase 3 58 ritonavir boosted 58 ImmuKnow R 58 Phase III ADT 58 human microdosing 58 liposomal formulation 58 genotype phenotype 58 EXPAREL ™ 58 metabolite identification 58 adecatumumab 58 Rigorous scientific 58 IMP# 58 depsipeptide 58 CIMZIA TM certolizumab pegol 58 vitro dissolution 58 florbetaben 58 Valortim ® 58 #I TM# 58 posaconazole 58 tumor histology 58 TOLAMBA 58 NeuroSTAT ® 58 KRAS mutation 58 eNO 58 insulin degludec 58 tumorigenicity 58 bortezomib Velcade 58 alpha fetoprotein AFP 58 LHRH receptor positive 58 phase IIb clinical 58 nanopharmaceutical 58 dacarbazine chemotherapy 58 prucalopride 58 pharmacodynamic profiles 58 Prodarsan ® 58 Alocrest 58 Omacetaxine 58 microdose 58 CanAg 58 IMiDs ® compound 58 multicenter randomized controlled 58 rxRNA 58 APEX AMI 58 LT NS# 58 Tarceva TM 58 TMC# C# 58 prospective randomized multicenter 58 ADVANCE PD 58 multicentre prospective 58 EndoTAGTM 1 58 antitumor effect 58 serum lipid levels 58 SYNTAX trial 58 Cardiotoxicity 58 Lp PLA 2 58 Androxal TM 58 peptide conjugated 58 SWOG 58 linear pharmacokinetics 58 NN# [001] 58 QLT# 58 oral FTY# 58 imetelstat 58 oral dnaJP1 58 ADVEXIN therapy 58 cMET 58 dose cohort 58 Phase III multicenter 58 USL# 58 OBPM 58 metaglidasen 58 retaspimycin 58 SinuNase ™ 58 Archexin 58 ExTRACT TIMI 58 placebo controlled Phase III 58 DNA methylation markers 58 CBLC# 58 vildagliptin 58 IFN α 58 clinicopathological 58 VeriStrat 58 Phase 2b kidney transplant 58 GLP toxicology 58 Insulin PH# 58 atazanavir ritonavir 58 Tarvacin TM 58 mGluR5 NAM 58 LUX Lung 58 Dacogen injection 58 Bayer HealthCare Onyx Pharmaceuticals 58 Phase IIa clinical 58 HDL Selective Delipidation 58 TACI Ig 58 Allovectin 7 ® 58 Amrubicin 58 HORIZONS AMI 58 immunogenicity 58 Spiegelmer ® 58 AST ALT 58 oral ibandronate 58 Platinol ® cisplatin 58 histamine dihydrochloride 58 Altastaph 58 glufosfamide 58 concurrent chemoradiation 58 Vaxfectin R adjuvant 58 Hedgehog inhibitor 58 HORIZONS AMI trial 58 potency selectivity 58 Phase #/#a trial 58 GLYX 58 relapsed MCL 58 midstage clinical 58 randomized discontinuation trial 58 Phase 2a trial 58 subcutaneously administered 58 TMC# [002] 58 placebo controlled multicenter 58 optimal dosing regimens 58 PRIMO CABG 58 administered subcutaneously 58 peripheral blood mononuclear 58 cytotoxicity assays 58 TriGrid 58 ACCORD Eye 58 Phase IIIb clinical 58 FOLPI 58 selective modulator 58 nucleotide analog 58 pramlintide 58 BENICAR HCT 58 placebo controlled Phase 58 lintuzumab 58 anti JCV antibody 58 coadministration 58 reactogenicity 58 glycosylated hemoglobin HbA1c 58 ER CHOP 58 HGS ETR2 58 Darinaparsin 58 Cardiorespiratory fitness 58 APTIVUS r 58 recombinant PSMA vaccine 58 predictive biomarker 58 metaanalysis 58 hemagglutination inhibition 58 Vaxfectin 58 epigenetic therapies 58 CIMZIA TM 58 anticancer activity 58 GOUT 58 Tanespimycin 58 ALV# 58 prospective randomized controlled 58 bepotastine besilate nasal spray 57 IMPROVE HF 57 RLY# 57 alicaforsen enema 57 darunavir ritonavir 57 immunological responses 57 NOXAFIL Oral Suspension 57 non nucleoside 57 IDX# 57 oral deforolimus 57 ganaxolone 57 REMINYL ® 57 subcutaneous formulation 57 conditional logistic regression 57 RECORD1 57 predictive toxicology 57 Phase IIa trial 57 excretion ADME 57 cathepsin K inhibitor 57 sargramostim 57 OncoVEX GM CSF 57 randomized controlled multicenter 57 PRT# 57 Phase 2a clinical trials 57 CaPSURE 57 Triapine R 57 APPRAISE 57 TransVax ™ 57 rALLy clinical trial 57 efficacy tolerability 57 CTA# Injection 57 transcriptomic 57 resminostat 57 mg/m2 cohort 57 Tumor Response 57 REG1 57 Prostate AdenoCarcinoma Treatment 57 Zevalin consolidation 57 Phase III randomized controlled 57 microRNA biomarkers 57 PDX pralatrexate 57 custirsen 57 eTag assays 57 skin sterol 57 potent suppressor 57 Enhanze Technology 57 randomized multicenter Phase III 57 molecular biomarker 57 PIX# [002] 57 Phase III ThermoDox 57 Bezielle 57 ABSORB trial 57 afatinib 57 TPI ASM8 57 TriRima 57 BAL# [002] 57 OMP #M# 57 VADT 57 dosage regimens 57 null responder HCV 57 antioxidant supplementation 57 antitumour 57 ChronVac C ® 57 next generation URAT1 57 unique alkylating agent 57 inhaled AAT 57 atherosclerosis regression 57 Anticalin ® 57 bazedoxifene conjugated estrogens 57 Vidaza azacitidine 57 clinical efficacies 57 retapamulin 57 XL# SAR# 57 CELVAPAN H#N# 57 glycemia 57 cardioprotective effects 57 Onrigin 57 OnDose TM 57 SELDI TOF MS 57 PERSEUS 57 Symadex 57 ACOSOG Z# 57 TAXUS ATLAS 57 cariprazine 57 JAK inhibitors 57 FOLFOX6 chemotherapy regimen 57 mg kg BID 57 EGFR HER2 57 RGB # 57 PI3K/Akt pathway inhibitor 57 CAMMS# 57 NICE SUGAR 57 K RAS 57 OHR/AVR# 57 HGS ETR1 57 microRNA profiling 57 prospective observational cohort 57 ISTODAX 57 receptor inhibitor 57 staphylococcal vaccine 57 Plicera 57 EKC Cide 57 Cloretazine R 57 AAG geldanamycin analog 57 compound AEZS 57 Flow cytometry 57 investigational hepatitis C 57 LibiGel ® 57 uricase 57 immunohistochemical 57 vivo toxicology 57 oral picoplatin 57 multicenter phase 57 Phase IIB 57 JAK inhibitor 57 PSN# [001] 57 basal insulin analogue 57 Apoptone 57 RE LY 57 Dataflow Manager 57 intravenous CK # 57 cyclophilin inhibitors 57 serum leptin 57 multicenter prospective 57 Forodesine HCl 57 hGH CTP 57 PA# [002] 57 pharmacokinetic profile 57 Annamycin 57 pharmacogenetic testing 57 thymalfasin 57 prospective nonrandomized 57 mertansine 57 entinostat 57 sorafenib tablets 57 genomic biomarker 57 ACCORD Lipid 57 OvaRex R 57 flow cytometric 57 PDE# inhibitors 57 BETAS 57 StemEx R 57 randomized multicenter 57 efficacy 57 subcutaneous doses 57 Glufosfamide 57 CALGB # [002] 57 AVOREN 57 teduglutide 57 KNS # 57 Curaxin 57 murine models 57 novel oral anticoagulant 57 MP4OX 57 TQT studies 57 SPIRIT FIRST 57 Pharmacokinetics PK 57 rhFVIIa 57 AIR CF1 57 HCV SPRINT 57 Vaxfectin R 57 Proellex TM 57 Ophena TM 57 TG# [003] 57 insulin lispro 57 afamelanotide 57 BEXXAR Therapeutic Regimen 57 durable pain palliation 57 oral ridaforolimus 57 eculizumab therapy 57 CHARISMA trial 57 aplindore 57 sorafenib Nexavar ® 57 Combo Stent 57 TEMSO 57 PRTX 57 bortezomib Velcade R 57 MORAb 57 MDCT scans 57 antiretroviral naïve 57 exploratory endpoints 57 multicenter trials 57 PDE4 inhibitor 57 XmAb# 57 hydroxy vitamin D 57 EC Cysteamine 57 Guanilib 57 p# inhibitor 57 tolerability profile 57 CRMD# 57 endoscopic remission 57 serum lipids 57 opioid naive 57 PITX2 methylation 57 KRN# 57 DiLA2 57 ritonavir boosted danoprevir 57 CYP#D# inhibitor 57 inhaled iloprost 57 IRX 2 57 Valdoxan 57 triple nucleoside 57 dose escalation 57 observational cohort 57 LungSign TM 57 serum concentrations 57 PRESEPT study 57 ESBA# 57 CYT# 57 apolipoproteins 57 tolerated dose MTD 57 Secondary endpoints include 57 PRECISE 57 CATIE AD 57 lomitapide 57 dose dose escalation 57 surrogate endpoint 57 talabostat 57 NNRTI resistant virus 57 paricalcitol 57 tacrolimus ointment 57 pathophysiological effects 57 AIR# [001] 57 daily subcutaneous injections 57 RRMS patients 57 TransVax tm 57 EGFR mutation status 57 bioequivalency 56 Phase III confirmatory 56 postprandial glycemia 56 tramiprosate Alzhemed TM 56 pegylated interferon alfa 2b 56 cilengitide 56 Wellmune WGP 56 antitumor efficacy 56 assessing T DM1 56 sorafenib Nexavar 56 nucleoside analog 56 silico prediction 56 evaluating Nexavar 56 putative biomarkers 56 Vaxfectin TM formulated 56 CDK inhibitor 56 HIV RDEA# 56 lispro 56 mutated K ras 56 BACcel ™ system 56 biologic plausibility 56 ABSORB clinical 56 GRN#L 56 PEGylated interferon 56 torezolid phosphate 56 prospective multicenter 56 neuropsychological assessments 56 neoadjuvant treatment 56 phase IIb III 56 novel VDA molecule 56 Edge STudy 56 ONTARGET 56 Omacetaxine mepesuccinate 56 hA# 56 biodistribution studies 56 EDEMA3 trial 56 metastatic neuroendocrine tumors 56 SYMMETRY trial 56 BEZ# 56 specified primary endpoint 56 PORxin TM 56 immunomodulation 56 nutrigenomic 56 CaPre TM 56 Dalbavancin 56 Phase III HEAT 56 Cloretazine ® 56 NCCN guidelines 56 cediranib 56 IMiDs R 56 relapsed myeloma 56 INSPIRE Trial Phase III 56 Fc gamma receptor 56 vivo assays 56 VNP#M 56 UPLYSO 56 GRAVITAS trial 56 EVEREST II 56 undetectable HBV DNA 56 Zybrestat 56 treatment naive genotype 56 MAQC 56 ixabepilone 56 DLTs 56 prospectively stratified 56 ENDEAVOR III 56 IMiDs ® 56 ROCKET AF 56 oral renin inhibitor 56 mg administered orally 56 Kinoid 56 vicriviroc 56 lesional 56 metabonomics 56 histone deacetylase inhibitor 56 posttest 56 GSK# [001] 56 fidaxomicin Phase 56 vascular disrupting agents 56 Aryplase 56 Mipomersen 56 NovoTTF 56 eprotirome 56 trial evaluating PRX# 56 eTag assay 56 vitro experiments 56 canakinumab 56 ritonavir boosted protease inhibitor 56 multiple logistic regression 56 registrational trial 56 R# #mg BID 56 cisplatin gemcitabine 56 AVERROES 56 metabolic parameters 56 SILENOR TM 56 refractory CLL 56 hemostatic efficacy 56 Hsp# Inhibitor 56 K ras mutations 56 PORxin TM platforms 56 favorable pharmacokinetic 56 NEVO RES 56 palifosfamide 56 multicenter Phase 56 ZOLINZA 56 registrational 56 management biostatistical analysis 56 NT proBNP assay 56 redox active 56 urate lowering 56 Eligen R B# 56 prospective randomized placebo 56 CCR5 mAb 56 KRAS status 56 Fasting glucose 56 CTA# 56 designated HVTN 56 oral Xeloda 56 MelaFind pivotal 56 serum lipid 56 refractory chronic lymphocytic 56 ELISpot 56 inferential statistics 56 ENDEAVOR IV 56 Hyphanox 56 VAX# 56 oral ghrelin agonist 56 multicenter randomized placebo controlled 56 ICON7 56 urocortin 2 56 calculated creatinine clearance 56 ZACTIMA 56 EDEMA3 56 somatostatin analog 56 BioNumerik 56 decitabine 56 PET tracers 56 prognostic indicators 56 Logistic regression 56 retrospective observational study 56 Vacc 4x 56 PRECiSE 56 prospective observational 56 haematologic 56 animal xenograft models 56 Prospective Randomized 56 GMX# 56 enzyme immunoassay EIA 56 TLR antagonists 56 NPM1 mutation 56 alefacept 56 CLL8 56 pharmacologically active isomer 56 fructosamine 56 oral methylnaltrexone 56 seliciclib CYC# 56 Targretin capsules 56 hyaluronidase enzyme 56 GATTEX ® 56 adjuvant endocrine therapy 56 ICAAC IDSA 56 serum phosphorous 56 Antiviral Activity 56 PXD# 56 GRNCM1 56 pan HDAC inhibitor 56 Vascugel R 56 gene expression assays 56 AEG# 56 biomarker discovery validation 56 generation purine nucleoside 56 APTIMA HPV 56 BN# [004] 56 ibandronate 56 NP2 56 posttreatment 56 QTinno TM 56 ragweed allergic 56 aclidinium bromide 56 AERAS-#/Crucell Ad# 56 Panzem NCD 56 topically administered 56 MET amplification 56 flavopiridol 56 huN# DM1 56 convergent validity 56 liprotamase 56 therapeutic monoclonal antibody 56 prospective multicenter study 56 Canvaxin TM 56 biodistribution 56 AKT inhibitor 56 Serological 56 N glycan 56 ALGRX 56 echocardiographic parameters 56 Pimavanserin 56 glycated hemoglobin levels 56 BAY #-# 56 ImmuKnow 56 everolimus eluting stents 56 unblinding 56 romidepsin 56 masked placebo controlled 56 AeroLEF TM 56 patientswith 56 abstracts summarizing 56 dose titration 56 lenalidomide Revlimid R 56 Maximum Tolerated Dose MTD